The drug maker announced the launch of icosapent ethyl capsules, 1 gram in the US market.
The product has received an approval by the United States Food and Drug Administration (USFDA). The drug is indicated to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.Dr. Reddy's icosapent ethyl is available in 1 gram capsules in bottle count size of 120 count.
On a consolidated basis, Dr Reddy's Laboratories' net profit dropped 28.7% to Rs 557.30 crore on 6.7% increase in net sales to Rs 4,728.40 crore in Q4 March 2021 over Q4 March 2020.
Dr Reddy's Laboratories is an integrated pharmaceutical company. Through its three businesses - pharmaceutical services & active ingredients, global generics and proprietary Products.
Shares of Dr Reddy's Laboratories lost 0.34% to Rs 5,261.50 on BSE. The stock hovered in the range of Rs 5,256.45 to Rs 5,309.30 so far.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app